First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0831
Full Text
Open PDFAbstract
Available in full text
Date
January 24, 2019
Authors
Publisher
American Association for Cancer Research (AACR)